Hydrogen study has “merit” — just not enough to avoid retraction

The International Journal of Hydrogen Energy has retracted a paper by a group from Malaysia and India who, reading between the lines, couldn’t quite get the low notes to overcome what the high notes lacked. Or something like that.

The paper, “Hydrogen production from sea water using waste aluminium and calcium oxide,” appears to have come out of the quaintly named 7th Petite Workshop on the Defect Chemical Nature of Energy Materials, held in March 2011 in Norway.

According to the notice: Continue reading Hydrogen study has “merit” — just not enough to avoid retraction

Update: Data fabricator had masters’ degree revoked

On Friday, we reported on the case of a retraction in the American Journal of Physiology — Cell Physiology by kinesiology researchers at Canada’s University of Waterloo for data fabrication by a graduate student, Sara Michelle Norris. We heard back from Waterloo yesterday, and have more details.

In our Friday post, we wondered whether Norris’s 2009 masters’ thesis,“Contribution of Sarcoplasmic Reticulum Calcium Pumping to Resting Mouse Muscle Metabolism,” might have been compromised. Waterloo tells us Norris is no longer at the university: Continue reading Update: Data fabricator had masters’ degree revoked

Data fabrication fells muscle physiology paper

Kinesiology researchers at the University of Waterloo in Canada have been forced to retract a 2010 paper in the American Journal of Physiology — Cell Physiology in the wake of revelations that the first author, then a graduate student, fabricated her data.

The paper, “ATP consumption by sarcoplasmic reticulum Ca2+ pumps accounts for 50% of resting metabolic rate in mouse fast and slow twitch skeletal muscle,” was written by Sarah Michelle Norris and colleagues and published in March 2010.

According to the retraction notice: Continue reading Data fabrication fells muscle physiology paper

Pfizer retracts study of experimental cancer treatment figitumumab for incorrect analyses

Pfizer has retracted a 2009 Journal of Clinical Oncology study purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.

Here’s the text of the notice: Continue reading Pfizer retracts study of experimental cancer treatment figitumumab for incorrect analyses

Lemus, Stapel each rack up another retraction

The retraction counts keep mounting for two Retraction Watch frequent flyers.

First, Diederik Stapel’s 26th retraction, according to our count. Psychologist Stapel admitted to making up data in dozens of studies, and is also facing a criminal inquiry for misuse of funds.

Here’s the notice: Continue reading Lemus, Stapel each rack up another retraction

Tie Retraction Syndrome? Fat chance

Every now and then, we’re accused of “gotcha journalism” here at Retraction Watch. But here’s the story of a paper that we hope you’ll agree is “gotcha” science of the best kind, involving a different kind of retraction. The research is of, shall we say, a pressing problem known as Tie Retraction Syndrome, or TRS for short, brought to the world’s attention by a group of ophthalmologists in Germany and the UK.

According to the paper in Orbit, TRS is: Continue reading Tie Retraction Syndrome? Fat chance

Loose lips sink paper on company’s experimental pain drug

A bit of intellectual property indiscretion has led to the retraction of a paper by Korean scientists. Although the details are fuzzy, several of the authors are affiliated with a Korean pharma company called SK.

The paper, “A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons,” was published in the The Korean Journal of Physiology & Pharmacology earlier this year.

According to the retraction notice: Continue reading Loose lips sink paper on company’s experimental pain drug

Gastro journal continues tough stance on duplication, with two new retractions

Monica Acalovschi is serious about ridding the literature of duplicate publications.

That would seem to be the message of two new retraction notices in the Journal of Gastrointestinal and Liver Diseases, which Acalovschi edits — two retractions that join another for similar reasons, which we covered earlier this year.

Here are the notices, from the June issue of the journal (but which were just indexed by Medline):

For “Intestinal Pseudo-obstruction – a Rare Condition with Heterogeneous Etiology and Unpredictable Outcome. A Case Report:” Continue reading Gastro journal continues tough stance on duplication, with two new retractions

Most retraction notices don’t involve research misconduct or flawed data: new study

October, apparently, is “studies of retractions month.” First there was a groundbreaking study in PNAS, then an NBER working paper, and yesterday PLoS Medicine alerted us to a paper their sister journal, PLoS ONE, published last week, “A Comprehensive Survey of Retracted Articles from the Scholarly Literature.”

The study, by Michael L. Grieneisen and Minghua Zhang, is comprehensive indeed, reaching further back into the literature than others we’ve seen, and also including more disciplines: Continue reading Most retraction notices don’t involve research misconduct or flawed data: new study

Collateral damage: What effect do retractions have on scientific funding?

Photo by Howard Lake via flickr http://www.flickr.com/photos/howardlake/

A new study from a group of Boston-area economists sheds some light on whether retractions have downstream effects on related fields, particularly when it comes to funding. From the abstract of the working paper, called simply “Retractions,” by  Pierre Azoulay, Jeffrey L. Furman, Joshua L. Krieger, and Fiona E. Murray:

We find that scientifi c misconduct stifle scientists’ pursuit of specifi c research lines, as we would anticipate if retraction events provide new signals of the fidelity of scienti fic knowledge. More centrally, our findings show that Continue reading Collateral damage: What effect do retractions have on scientific funding?